- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Modify Clinical Study Protocol: CDSCO Panel Tells Roche On Multiple Sclerosis Drug Ocrelizumab
New Delhi: In response to the proposal presented by drug major Roche to conduct the Phase IV clinical trial for the drug product Ocrelizumab 300 mg Concentrate for solution for infusion 300 mg/10 mL (30 mg/mL) in a single-dose vial, the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has suggested the firm to modify the protocol and to submit the revised protocol for the further evaluation.
This came after the drug major Roche presented the protocol to conduct a Phase IV clinical trial for the drug product Ocrelizumab 300 mg Concentrate for solution for infusion 300 mg/10 mL (30 mg/mL) in a single-dose vial titled “A Multi-Center, Open-Label, Single Arm Phase IV Study to assess the safety and effectiveness of Ocrelizumab in Multiple Sclerosis (RMS and PPMS) patients in India (Overture)” vide protocol ML45008, Version 1.0 dated 12 Jul 2023.
Multiple sclerosis (MS) is a chronic condition that causes nerve damage. The four main types of MS are clinically isolated syndrome (CIS), relapsing-remitting MS (RRMS), primary-progressive MS (PPMS), and secondary-progressive MS (SPMS).
Relapsing-remitting multiple sclerosis (RRMS) is the most common course of MS. If one has RRMS, one will experience clearly defined attacks of new or increasing neurologic symptoms. These attacks — also called “relapses” or “exacerbations” — are followed by periods of partial or complete recovery (remissions). Primary progressive multiple sclerosis (PPMS) is a type of multiple sclerosis (MS) where symptoms get worse over time.
Ocrelizumab is a medication that treats multiple sclerosis. It works by slowing down an overactive immune system to prevent or delay symptoms. MS affects the central nervous system.
Ocrelizumab is a medication used in the management and treatment of primary progressive and relapsing multiple sclerosis. It is in the anti-CD20 monoclonal antibody class of medications.
Ocrelizumab is an anti-CD20 antibody that depletes circulating immature and mature B cells but spares CD20-negative plasma cells. The effector mechanisms of anti-CD20 antibodies are complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity.
At the recent SEC meeting for Neurology and Psychiatry held on 18th and 19th January 2023, the expert panel reviewed the protocol presented by drug major Roche for conducting the Phase IV clinical trial for drug product Ocrelizumab 300 mg Concentrate for a solution for infusion 300 mg/10 mL (30 mg/mL) in a single-dose vial.
After detailed deliberation, the committee recommended the following changes in the protocol:
1. Follow-up should be done for a minimum of 2 years.
2. The efficacy endpoint should be included as the co-primary objective of the study.
3. One Government independent site with a neurologist should evaluate the patients whether the patient is truly progressive for the PPMS before enrolment in the study.
4. A minimum of 10% of PPMS patients should be included in the study.
5. The number of evaluable patients in the study should be a minimum of 32.
6. The study sites should be geographically distributed.
Following the above, the expert panel suggested that the firm be required to submit a revised protocol to CDSCO for further evaluation before the committee.
Also Read: COMP a novel predictor of CVD and CAD in RA
Doctor of Pharmacy
Dr. Divya Colin, a Doctor of Pharmacy Graduate with extensive experience in clinical and hospital settings and confidently equipped with diagnostic and therapeutic skills. She also has spread out exposure to Oncology Departments in Mysore Medical College and Research Institute as Oncology Pharmacist. Currently she is building a career in clinical research and clinical data management. She has been a part of Medical Dialogue since January 2022.
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751